Question 1

Has Chao-Huang Sun received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $455,189 in general payments to Chao-Huang Sun across 245 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Chao-Huang Sun did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Chao-Huang Sun come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Akebia Therapeutics Inc	148	$204,411
GSK	50	$146,606
Astrazeneca AB	3	$64,913
Baxter Healthcare	2	$14,500
Gilead	2	$7,553
Boehringer Ingelheim	2	$5,790
Dynavax Technologies Corporation	12	$4,403
Astrazeneca UK Limited	8	$3,544
CSL Behring	2	$1,937
Biogen	1	$1,131
Travere Therapeutics, Inc.	1	$149
AstraZeneca	6	$90
Amgen(2 entities)	4	$82
Boehringer Ingelheim International GmbH	1	$26
Vifor Pharma, Inc.	1	$25
Genentech USA, Inc.	1	$16
Fresenius USA Marketing, Inc.	1	$12

Chao-Huang Sun

Payments from drug & device makers

Who reported the general payments

How this compares

Other nephrology in Riverside